Revance Therapeutics

RVNC64

Penny Stock

$3.73arrow_drop_down2.86%-$0.10

Penny Stock

RVNC64

$3.73

arrow_drop_down2.86%-$0.10

Penny Stock

Performance History

Key Stats
Open	$3.84
Prev. Close	$3.84
EPS	-3.34
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$391.28M
PE Ratio	-

	LOW	HIGH
Day Range	3.69	3.96
52 Week Range	2.30	10.71

Ratios







EPS	-3.34

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Revance Therapeutics (RVNC)

Revance Therapeutics is a biotechnology company focused on developing innovative products in the field of aesthetic medicine. The company's main product is DaxibotulinumtoxinA, a potential alternative to Botox that is currently in development. DaxibotulinumtoxinA has shown promising results in clinical trials, with patients experiencing long-lasting results and fewer side effects compared to existing treatments. If approved, DaxibotulinumtoxinA could disrupt the market for aesthetic treatments and become a major revenue driver for Revance Therapeutics.

In addition to DaxibotulinumtoxinA, Revance Therapeutics is also developing a range of other products targeting different areas of aesthetic medicine. These include a dermal filler with longer-lasting effects than current products on the market, as well as a treatment for excessive sweating. The company's pipeline is backed by strong scientific research and a team of experienced researchers and clinicians.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Mr. Mark J. Foley
Headquarters: Nashville
Employees: 534
Exchange: NASDAQ

Keep an eye on Revance Therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Revance Therapeutics 's (RVNC) price per share?

The current price per share for Revance Therapeutics (RVNC) is $3.73. The stock has seen a price change of -$0.11 recently, indicating a -2.86% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Revance Therapeutics (RVNC)?

For Revance Therapeutics (RVNC), the 52-week high is $10.71, which is 187.13% from the current price. The 52-week low is $2.3, the current price is 62.17% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Revance Therapeutics (RVNC) a growth stock?

Revance Therapeutics (RVNC) has shown an average price growth of -3.66% over the past three years. It has received a score of 25 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Revance Therapeutics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Revance Therapeutics (RVNC) stock price performance year to date (YTD)?

As of the latest data, Revance Therapeutics (RVNC) has a year-to-date price change of -59.94%. Over the past month, the stock has experienced a price change of -29.49%. Over the last three months, the change has been -43.48%. Over the past six months, the figure is 39.7%. Looking at a longer horizon, the five-year price change stands at -77.98%.

help

Is Revance Therapeutics (RVNC) a profitable company?

Revance Therapeutics (RVNC) has a net income of -$323.99M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 34.98% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -53.87% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $234.04M, with a revenue growth rate of 76.55%, providing insight into the company's sales performance and growth. The gross profit is $81.88M. Operating income is noted at -$316.78M. Furthermore, the EBITDA is -$187.62M.

help

What is the market capitalization of Revance Therapeutics (RVNC)?

Revance Therapeutics (RVNC) has a market capitalization of $391.29M. The average daily trading volume is 3.8, indicating the stock's liquidity and investor engagement.